Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2005-12-20
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT00267059
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Lenalidomide and Docetaxel in Treating Patients With Advanced Solid Tumors
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2010-06-11
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT00253344
- Locations
- 🇺🇸
Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
- First Posted Date
- 2005-10-13
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 97
- Registration Number
- NCT00238238
- Locations
- 🇺🇸
Menorah Medical Center, Overland Park, Kansas, United States
🇺🇸Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
🇺🇸Memorial Hospital, Carthage, Illinois, United States
Lenalidomide and Prednisone in Treating Patients With Myelofibrosis
- Conditions
- Essential ThrombocythemiaPrimary MyelofibrosisPolycythemia Vera
- Interventions
- First Posted Date
- 2005-09-28
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00227591
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 50
- Registration Number
- NCT00179660
- Locations
- 🇺🇸
UC David Cancer Center, Sacramento, California, United States
🇺🇸New York Medical Center, MBCCOP, Bronx, New York, United States
🇺🇸Sylvester Cancer CenterUniversity Of Miami, Miami, Florida, United States
Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
- Conditions
- Ovarian Cancer
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT00179712
- Locations
- 🇺🇸
Medical College of GeorgiaDept of OBGYN, Augusta, Georgia, United States
🇺🇸University of MinnesotaObstetrics & Gynecology, MMC, Minneapolis, Minnesota, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2010-03-16
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 1913
- Registration Number
- NCT00179647
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸Cedar Sinai Medical CenterDept of Medicine, Los Angeles, California, United States
Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality
- Conditions
- Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 205
- Registration Number
- NCT00179621
- Locations
- 🇧🇪
AZ St-Jan Brugge AV, Brugge, Belgium
🇧🇪UZ Gasthuisberg, Leuven, Belgium
🇧🇪CHU Mont Godine, Yvoir, Belgium
A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2006-12-20
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT00179686
- Locations
- 🇺🇸
Cancer and Blood Institute, Metairie, Louisiana, United States
🇺🇸Rush Cancer Institute, Chicago, Illinois, United States
🇺🇸Birmingham Cancer Center, Birmingham, Alabama, United States
Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
- Conditions
- Ovarian Cancer
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2006-04-12
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT00179725
- Locations
- 🇺🇸
MD Anderson Cancer Center Orlando, Orlando, Florida, United States
🇺🇸OU Health Sciences Center, Oklahoma City, Oklahoma, United States
🇺🇸University of California at San Francisco, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.